Genentech Says Data Positive From Tecentriq Lung Cancer Study

Date : 09/27/2019 @ 3:20PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 38.16  -0.28 (-0.73%) @ 8:59PM
After Hours
Last Trade
Last $ 38.16 ◊ 0.00 (0.00%)

Genentech Says Data Positive From Tecentriq Lung Cancer Study

Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Roche Holding (QX) Charts.

By Michael Dabaie

 

Roche Holding AG's (RO.EB, ROG.EB) Genentech said data was positive from the Phase III IMpower110 study evaluating Tecentriq in advanced non-squamous and squamous non-small cell lung cancer.

Genentech said the study looked at Tecentriq as a monotherapy in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations.

The study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer with high PD-L1 expression live longer compared with chemotherapy alone, Genentech said.

The company said it will share the data with health authorities globally, including the U.S. Food and Drug Administration and European Medicines Agency.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

September 27, 2019 11:05 ET (15:05 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.